A clinical stage, type 1 diabetes immunotherapy project needed convincing partnering materials and advice on data room structure and due diligence preparations.
We overhauled the presentation of the project, highlighting the mechanism-based approach to treating and preventing type 1 diabetes, and the scientific rationale of the approach being taken.
The presentation was professional, with consistent style and encompassed scientific rationale, clinical data and supporting preclinical data. We benchmarked it against other competing therapies, IP and future product development strategies.
The program was subsequently out-licensed to a major pharma company for further development.Back